Published in Br J Pharmacol on May 01, 1970
A third class of anti-arrhythmic action. Effects on atrial and ventricular intracellular potentials, and other pharmacological actions on cardiac muscle, of MJ 1999 and AH 3474. Br J Pharmacol (1970) 2.78
Comparison of propranolol and LB 46 (prinodolol) on hyperthyroid tachycardia. Postgrad Med J (1971) 0.90
Comparison of propranolol and Ro 3-3528 in hyperthyroid tachycardia and dysrhythmias. Postgrad Med J (1973) 0.90
Alprenolol and propranolol in hyperthyroid tachycardia. Br J Pharmacol (1970) 0.78
Adrenergic beta-receptor blockade in hyperthyroidism. Br J Clin Pharmacol (1975) 0.77
Intrinsic heart rate on exercise and the measurement of beta-adrenoceptor blockade. Br J Clin Pharmacol (1976) 0.75
The assessment of β-adrenoceptor blocking drugs in hyperthyroidism. Br J Clin Pharmacol (1974) 0.75
Beta-adrenergic blocking drugs and thyroid function. Br Med J (1977) 0.75
Sotalol for the protection of turkeys from the development of -aminopropionitrile-induced aortic ruptures. Br J Pharmacol (1972) 0.75
Pharmacology of a new adrenergic beta-receptor-blocking compound (Nethalide). Lancet (1962) 11.41
Comparison of the effects of I.C.I. 50172 and propranolol on the cardiovascular responses to adrenaline, isoprenaline and exercise. Br J Pharmacol (1968) 4.20
THE EFFECTS ON CARDIAC MUSCLE OF BETA-RECEPTOR ANTAGONISTS IN RELATION TO THEIR ACTIVITY AS LOCAL ANAESTHETICS. Br J Pharmacol Chemother (1965) 3.38
Preliminary investigations of a new beta-adrenoceptive receptor blocking drug, LB46, in man. Br J Pharmacol (1969) 3.25
Pharmacological and toxicological properties of two new beta-adrenergic receptor antagonists. J Pharmacol Exp Ther (1965) 2.81
Perspectives in adrenergic beta-receptor blockade. Clin Pharmacol Ther (1969) 2.29
Effect of beta adrenergic blockade on the hemodynamic responses to epinephrine in man. Am J Cardiol (1966) 1.97
A comparison of three beta-adrenergic receptor-blocking drugs in thyrotoxic tachycardia. J Clin Pharmacol J New Drugs (1968) 1.40
Inotropic and chronotropic effects of a series of beta-adrenergic blocking drugs: some structure-activity relationships. Proc Soc Exp Biol Med (1966) 1.37
Myocardial and local anesthetic actions of beta-adrenergic receptor blocking drugs: relationship to physicochemical properties. Eur J Pharmacol (1968) 1.12
The role of the thyroid in the control of heart-rate. Lancet (1968) 1.10
Sotalol: a new, safe beta adrenergic receptor blocking agent. Am J Cardiol (1968) 1.02
Inhibition of cardiac chronotropic action of isoproterenol by Sotalol (MJ 1999) in rat, dog and man. Curr Ther Res Clin Exp (1967) 1.00
Potency and time-effect relationship in man of propranolol and H 56-28--comparative studies after oral administration. Acta Pharmacol Toxicol (Copenh) (1967) 0.83
Selective blockade of adrenoceptive beta receptors in the heart. Br J Pharmacol Chemother (1968) 14.80
Comparison of some properties of pronethalol and propranolol. Br J Pharmacol Chemother (1965) 4.71
Comparison of the effects of I.C.I. 50172 and propranolol on the cardiovascular responses to adrenaline, isoprenaline and exercise. Br J Pharmacol (1968) 4.20
The pharmacology of beta sympathetic blockade. Am J Cardiol (1966) 3.96
Clinical pharmacologic observations on atenolol, a beta-adrenoceptor blocker. Clin Pharmacol Ther (1976) 3.16
Optical isomers of propranolol. Nature (1966) 3.09
The cardio-toxicity of isoprenaline during hypoxia. Br J Pharmacol (1969) 2.94
Unexpected changes to the global methane budget over the past 2000 years. Science (2005) 2.61
The clinical pharmacology of mexiletine. Br J Clin Pharmacol (1978) 2.56
Controlled trial of propranolol in thyrotoxicosis. Lancet (1969) 2.54
The effect of propranolol on the cardiovascular responses to isoprenaline, adrenaline and noradrenaline in the anaesthetized dog. Br J Pharmacol Chemother (1966) 2.52
Cardio-selective beta-blockade. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol (1968) 2.33
Apoptosis of human intestinal epithelial cells after bacterial invasion. J Clin Invest (1998) 2.32
The effect of Kö 1173, a new anticonvulsant agent on experimental cardiac arrhythmias. Br J Pharmacol (1972) 2.11
A double-blind comparative clinical trial of mefloquine and chloroquine in symptomatic falciparum malaria. Bull World Health Organ (1983) 2.10
A confidential study of deaths after emergency medical admission: issues relating to quality of care. Clin Med (2003) 2.10
The clinical pharmacology of beta adrenergic blocking drugs. J R Coll Physicians Lond (1976) 1.94
National Poisons Information Services: report and comment 1980. Br Med J (Clin Res Ed) (1981) 1.91
Oral mexiletine in high-risk patients after myocardial infarction. Lancet (1981) 1.91
The peripheral vascular effects of propranolol and related compounds. Br J Pharmacol Chemother (1967) 1.87
The effect of experimental cardiac arrhythmias of a new anticonvulsant agent, Kö 1173, and its comparison with phenytoin and procainamide. Br J Pharmacol (1970) 1.81
Blood levels of practolol after oral and parenteral administration and their relationship to exercise heart rate. Clin Pharmacol Ther (1974) 1.81
Influence of intrinsic sympathomimetic activity and cardioselectivity on beta adrenoceptor blockade. Clin Pharmacol Ther (1977) 1.77
Observations on the efficacy and pharmacokinetics of sotalol after oral administration. Eur J Clin Pharmacol (1976) 1.71
Mexiletine (Kö 1173) in the management of ventricular dysrhythmias. Lancet (1973) 1.68
Role of intestinal epithelial cells in the host secretory response to infection by invasive bacteria. Bacterial entry induces epithelial prostaglandin h synthase-2 expression and prostaglandin E2 and F2alpha production. J Clin Invest (1997) 1.68
Some pharmacological properties of a new adrenergic beta-receptor antagonist. Nature (1966) 1.66
Effects of the beta 2-adrenoceptor antagonist ICI 118,551 on exercise tachycardia and isoprenaline-induced beta-adrenoceptor responses in man. Br J Clin Pharmacol (1985) 1.65
Propranolol and the utilization of radioiodine by the human thyroid gland. Acta Endocrinol (Copenh) (1969) 1.63
Effect of propranolol on arrhythmias following coronary artery occlusion in dogs. Cardiovasc Res (1967) 1.61
Neonatal thyrotoxicosis treated with propranolol. Arch Dis Child (1974) 1.59
Comparison of the activity and plasma levels of oxprenolol, slow release oxprenolol, long acting propranolol and sotalol. Eur J Clin Pharmacol (1980) 1.57
Comparison of the efficacy and pharmacokinetics of conventional propranolol and a long acting preparation of propranolol. Br J Clin Pharmacol (1980) 1.55
Stimulation of adrenergic beta-receptors by orciprenaline. Br Med J (1967) 1.52
Debendox and congenital malformations in Northern Ireland. Br Med J (1980) 1.46
Clinical pharmacology methodology: introduction. Br J Clin Pharmacol (1978) 1.39
Comparison of the effect of propranolol, lignocaine, and other drugs on normal and raised intraocular pressure in man. Am J Ophthalmol (1971) 1.37
Spectrophotofluorometric and gas-liquid chromatographic methods for the estimation of mexiletine (Kö 1173) in plasma and urine. J Pharm Pharmacol (1973) 1.36
Duration of action of beta-blocking drugs. Br Med J (1973) 1.33
Effects of alinidine, a novel bradycardic agent, on heart rate and blood pressure in man. J Cardiovasc Pharmacol (1982) 1.32
Propranolol and iodine-131 in the management of thyrotoxicosis. Lancet (1968) 1.29
Stimulation of gastrin release by catecholamines. Lancet (1972) 1.26
Effects on exercise tachycardia during forty-eight hours of a series of doses of atenolol, sotalol, and metoprolol. Clin Pharmacol Ther (1981) 1.23
Effects of the myocardial-selective alpha 1-adrenoceptor antagonist UK-52046 and atenolol, alone and in combination, on experimental cardiac arrhythmias in dogs. Br J Pharmacol (1988) 1.17
Cardiovascular effects of alinidine and propranolol alone and in combination with hydralazine in normal man. Br J Clin Pharmacol (1983) 1.16
Correlation of reduction of exercise heart rate with blood levels of atenolol after oral and intravenous administration. Postgrad Med J (1977) 1.13
Is verapamil a beta-blocker? Lancet (1968) 1.11
The role of the thyroid in the control of heart-rate. Lancet (1968) 1.10
The development of mexiletine in the management of ventricular dysrhythmias. Postgrad Med J (1977) 1.09
The pharmacokinetics of vincristine in man: reduced drug clearance associated with raised serum alkaline phosphatase and dose-limited elimination. Cancer Chemother Pharmacol (1982) 1.08
Alinidine reduces heart-rate without blockade of beta-adrenoceptors. Lancet (1981) 1.06
Studies on sweating in clinical and experimental thyrotoxicosis. Clin Sci Mol Med (1973) 1.06
Effects of lignocaine and propranolol on experimental cardiac arrhythmias. Br J Pharmacol (1971) 1.04
Characterization of the beta-adrenoreceptors which mediate the isoprenaline-induced changes in finger tremor and cardiovascular function in man. Eur J Clin Pharmacol (1988) 1.03
Effects of ICI 141,292 on exercise tachycardia and isoprenaline-induced beta-adrenoceptor responses in man. Br J Clin Pharmacol (1986) 1.01
The effect of the dextro isomer of propranolol on sinus rate and cardiac arrhythmias. Am Heart J (1968) 1.01
The properties of beta-adrenoceptor antagonists. Postgrad Med J (1976) 1.00
Comparison of the effects of isoprenaline, orciprenaline, salbutamol and isoetharine on the cardiovascular system of anaesthetized dogs. Br J Pharmacol (1971) 1.00
The selectivity of xamoterol, prenalterol, and salbutamol as assessed by their effects in the presence and absence of ICI 118,551. J Cardiovasc Pharmacol (1988) 1.00
Observation on the efficacy and pharmacokinetics of betaxolol (SL 75212), a cardioselective beta-adrenoceptor blocking drug. Br J Clin Pharmacol (1981) 1.00
Suppression of ventricular arrhythmias after coronary artery ligation by pinacidil, a vasodilator drug. J Cardiovasc Pharmacol (1985) 0.98
A comparison of the cardiovascular actions of four adrenergic -receptor blocking agents in resting, conscious dogs. Am Heart J (1971) 0.97
Mexiletine in normal volunteers. Br J Clin Pharmacol (1978) 0.97
Comparison of the duration of effect of metoprolol and a sustained release formulation of metoprolol (betaloc-SA). Br J Clin Pharmacol (1981) 0.96
Pharmacokinetics of low-dose methotrexate in children receiving maintenance therapy for acute lymphoblastic leukaemia. Cancer Chemother Pharmacol (1982) 0.94
Clinical pharmacokinetics of beta-adrenoceptor antagonists. An update. Clin Pharmacokinet (1987) 0.90
Inhibition of the carotid sinus reflex by the chronic administration of propranolol. Br J Pharmacol (1969) 0.89
Studies of the agonist and antagonist activity of cicloprolol in man. Eur J Clin Pharmacol (1988) 0.89
Celiprolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties and its therapeutic use in hypertension and angina pectoris. Drugs (1987) 0.89
Changes in heart rate and forearm blood flow following intravenous boluses of isoprenaline in the presence of practolol and propranolol. Br J Clin Pharmacol (1983) 0.88
Slow release beta-adrenoceptor blocking drugs. J R Coll Physicians Lond (1983) 0.88
A comparison of the cardioselectivity of five beta-adrenoceptor blocking drugs. J Cardiovasc Pharmacol (1987) 0.87
Further observations on the cardiotoxicity of isoprenaline during hypoxia. Br J Pharmacol (1974) 0.87
Alinidine pharmacokinetics following acute and chronic dosing. Br J Clin Pharmacol (1982) 0.87
Investigation into mechanism of lack of reflex tachycardia in response to hypotensive action of indoramin in dogs. J Cardiovasc Pharmacol (1984) 0.87
Differential blockade of alpha-adrenoceptors by indoramin. Br J Clin Pharmacol (1984) 0.86
Can severe vincristine neurotoxicity be prevented? Cancer Chemother Pharmacol (1982) 0.86
Cardiovascular effects of indoramin in man--a dose ranging study. Br J Clin Pharmacol (1983) 0.86
Effect of very early intervention with metoprolol on myocardial infarct size. Br Heart J (1983) 0.85
Narcolepsy in the elderly: a forgotten diagnosis. Age Ageing (1987) 0.85
Management of clinical trials in developing countries. J Int Med Res (1983) 0.85
The surgery of 'inguino-femoral' lymph nodes: is it adequate or excessive? Int J Gynecol Cancer (2004) 0.85
A comparative pharmacokinetic study of conventional propranolol and long acting preparation of propranolol in patients with cirrhosis and normal controls. Br J Clin Pharmacol (1987) 0.84
Evaluation of once daily sotalol administration in man. Br J Clin Pharmacol (1977) 0.84
Acute haemodynamic effects of pinacidil in man. Br J Clin Pharmacol (1986) 0.84
Effects of betaxolol, propranolol, and atenolol on isoproterenol-induced beta-adrenoceptor responses. Clin Pharmacol Ther (1985) 0.84
Human pharmacokinetic and pharmacodynamic studies on Ro31-1118, a new beta-adrenoceptor antagonist. Br J Clin Pharmacol (1985) 0.83
Long term follow up of patients treated for hyperthyroidism with low dose radioactive iodine. Ulster Med J (1980) 0.83
Adrenaline-induced lignocaine-resistant dysrhythmias in experimental myocardial infarction. Am Heart J (1974) 0.83
Effects of azepexole and clonidine on baroreceptor mediated reflex bradycardia and physiological tremor in man. Br J Clin Pharmacol (1985) 0.83
Very early intervention with metoprolol in suspected acute myocardial infarction. Eur Heart J (1985) 0.82
Cardiovascular effects of pinacidil and propranolol alone and in combination in normal humans. J Cardiovasc Pharmacol (1986) 0.82
Studies with a slow-release formulation of propranolol in angina. Ir Med J (1979) 0.82
An assessment of the partial agonist activity of Ro 31-1118, flusoxolol and pindolol in man. Br J Clin Pharmacol (1987) 0.82
Uses of beta-adrenoceptor blocking drugs. J R Coll Physicians Lond (1976) 0.82
Metabolic and cardiovascular effects of isoprenaline and salbutamol in the dog. Br J Pharmacol (1975) 0.82
The properties of beta adrenergic blocking agents. Ir J Med Sci (1969) 0.82
Comparison of some effects of glucagon and isoprenaline on the cardiovascular system of the anaesthetized dog. Br J Anaesth (1972) 0.81
Pharmacology, clinical pharmacology and potential therapeutic uses of the specific bradycardiac agent alinidine. Eur Heart J (1985) 0.81